Pharming Group NV 2022 AR2
The report highlights Pharming's strategic progress in 2022, notably the FDA approval of its second product, Joenja (leniolisib), in March 2023 for the treatment of APDS. The company achieved strong sales performance from its lead product, RUCONEST, which reached US$205.6 million in revenues. Pharming also launched its ESG program and established an internal ESG steering committee to build a sustainable business. Additionally, the company advanced its pre-clinical pipeline, including gene therapy OTL-105 for HAE, while strategically discontinuing non-rare disease assets.
Company: Pharming Group NV
Sector: Health Care
Country: Netherlands
Year: 2022
Type: AR2
Pages: 222
Pharming Group NV
Annual Report
The report highlights Pharming's strategic progress in 2022, notably the FDA approval of its second product, Joenja (leniolisib), in March 2023 for the treatment of APDS. The company achieved strong sales performance from its lead product, RUCONEST, which reached US$205.6 million in revenues. Pharming also launched its ESG program and established an internal ESG steering committee to build a sustainable business. Additionally, the company advanced its pre-clinical pipeline, including gene therapy OTL-105 for HAE, while strategically discontinuing non-rare disease assets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees